Core Viewpoint - Hansoh Pharmaceutical announced a licensing agreement with F. Hoffmann-La Roche Ltd for the global exclusive rights to develop, manufacture, and commercialize HS-20110, excluding mainland China, Hong Kong, Macau, and Taiwan [1] Group 1: Licensing Agreement Details - The agreement involves Hansoh's wholly-owned subsidiary Shanghai Hansoh Biopharmaceutical Technology Co., Ltd. and Changzhou Hengbang Pharmaceutical Co., Ltd. as licensors [1] - Hansoh will receive an upfront payment of $80 million and is eligible for up to $1.45 billion in milestone payments based on the product's development, regulatory approval, and commercialization progress [1] - The product, HS-20110, is an investigational CDH17-targeted antibody-drug conjugate (ADC) currently undergoing global Phase I clinical trials for colorectal cancer (CRC) and other solid tumors in China and the United States [1] Group 2: Company and Market Context - The licensee, F. Hoffmann-La Roche Ltd, is a subsidiary of Roche Holding AG, which is listed on the Swiss Stock Exchange [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) has entered into a licensing agreement with F. Hoffmann-La Roche Ltd for the global exclusive rights to develop, manufacture, and commercialize HS-20110, a CDH17-targeted antibody-drug conjugate, excluding mainland China, Hong Kong, Macau, and Taiwan [1] Group 1: Licensing Agreement Details - The agreement involves a payment of $80 million as an upfront fee to Hansoh Pharmaceutical [1] - Hansoh is eligible to receive up to $1.45 billion in milestone payments based on the product's development, regulatory approval, and commercialization progress [1] - Future potential sales will also generate tiered royalties for Hansoh [1] Group 2: Product and Clinical Trials - HS-20110 is currently undergoing global Phase I clinical trials for the treatment of colorectal cancer (CRC) and other solid tumors in both China and the United States [1] Group 3: Company Background - Roche Holding AG, the parent company of the licensee, is a leading global biotechnology company and a pioneer in the pharmaceutical manufacturing industry, established in 1896 in Basel, Switzerland [1] - The board of Hansoh believes that this licensing agreement aligns with the best interests of the company and its shareholders, maximizing the scientific and commercial value of its technology platform [1]

Core Insights - Hansoh Pharmaceutical (03692) announced a licensing agreement with F. Hoffmann-La Roche Ltd for the global exclusive rights to develop, manufacture, and commercialize HS-20110, excluding mainland China, Hong Kong, Macau, and Taiwan [1][2] - The agreement includes an upfront payment of $80 million, with potential milestone payments of up to $1.45 billion based on the product's development, regulatory approval, and commercialization progress, along with tiered royalties on future sales [1] - HS-20110 is an investigational CDH17-targeted antibody-drug conjugate (ADC) currently undergoing global Phase I clinical trials for the treatment of colorectal cancer (CRC) and other solid tumors in China and the United States [1] Company Overview - Roche Holding AG, the parent company of the licensee, is a leading global biotechnology company and a leader in in vitro diagnostics, established in 1896 in Basel, Switzerland [2] - The board of Hansoh Pharmaceutical believes that entering into this licensing agreement aligns with the overall best interests of the company and its shareholders, maximizing the scientific and commercial value of its technology platform [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3692） 內幕消息 與羅氏訂立許可協議 本公告乃由翰森製藥集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）根 據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第 571章證券及期貨條例第XIVA部的內幕消息條文（定義見上市規則）而作出。 根據許可協議，許可人將授予被許可人開發、生產及商業化HS-20110（「該產品」） 的全球獨佔許可（不含中國內地、香港、澳門和台灣）。許可人將獲得8,000萬美元 首付款，並有資格根據該產品開發、註冊審批和商業化進展收取最高14.5億美元 里程碑付款，以及未來潛在產品銷售的分級特許權使用費。 該產品是一款在研CDH17靶向抗體–藥物偶聯物(ADC)，目前正在中國和美國開 展用於治 ...

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 2.42% on October 16, with a trading volume of 1.486 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of October 15, 2024, the fund's shares reached 8.213 billion, with a total size of 7.102 billion yuan, reflecting a significant increase of 1977.25% in shares and 1779.88% in size compared to December 31, 2023 [1] Fund Performance - The current fund manager, Ma Jun, has achieved a return of 68.94% since taking over the fund on January 3, 2024 [2] - The ETF's top holdings include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant percentages of the portfolio allocated to these stocks [2] Trading Activity - Over the last 20 trading days, the ETF recorded a cumulative trading amount of 30.962 billion yuan, averaging 1.548 billion yuan per day [1] - Since the beginning of the year, the ETF has seen a total trading amount of 222.219 billion yuan over 189 trading days, averaging 1.176 billion yuan per day [1]

Core Viewpoint - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.6% and the Hang Seng Tech Index decreasing by 0.22% [1] Group 1: Market Performance - The pharmaceutical sector faced significant losses, with notable declines in specific companies [1] - Nocera Healthcare and SiHuan Pharmaceutical both dropped over 8% [1] - China Biologic Products and Hansoh Pharmaceutical saw declines exceeding 4% [1]

Group 1 - The stock price of Hansoh Pharmaceutical has decreased by 5.05%, currently trading at 37.6 HKD [1] - The total market capitalization of Hansoh Pharmaceutical is 227.74 billion HKD [1] - Year-to-date, Hansoh Pharmaceutical has experienced a cumulative increase of 120.03% [1]

Group 1 - The US stock market showed mixed performance, with the Dow Jones rising by 0.5%, while the Nasdaq initially increased before falling by 0.3%, and the S&P 500 remained stable [3] - The Golden Dragon Index, which reflects the performance of Chinese concept stocks, declined by 1.2% [3] Group 2 - The Hong Kong stock market performed well last week, with the Hang Seng Index gaining 1,012 points or 3.88%, closing at 27,140 points, while the Tech Index rose by 6.9% to close at 6,622 points [4] - Semiconductor company SMIC (00981.HK) was the best-performing constituent stock, rising nearly 25% over the week, with six other stocks also increasing by over 10%, including Kuaishou (01024.HK) up over 17% and Xinyi Solar (00968.HK) up 14.7% [4] - The worst-performing constituent stock was Pop Mart (09992.HK), which fell by over 4%, with its stock price down more than 25% from its peak [4] - Real estate-related stocks experienced adjustments, with China Resources Mixc (01209.HK) down 3.5%, Longfor (00960.HK) and R&F Properties (01109.HK) down nearly 2.4% and 1.8% respectively, while China Overseas (00688.HK) slightly outperformed peers with a 0.5% increase [4] - Zijin Mining's spin-off, Zijin Gold International (02259.HK), had a strong debut, being quickly included in the Hang Seng Composite Index, with its stock price closing at 120.6 HKD, nearly 90% higher than its IPO price [4] Group 3 - The Hang Seng Index remained above the 10-day moving average (26,600 points), indicating a stable trend, and as long as it stays above this level, the upward trend is expected to continue [5]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 翰森製藥集團有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03692 | 說明 | - | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.00001 | HKD | | 200,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.00001 | HKD | | 200,000 | 本月底法定 ...

Core Points - The Hang Seng Index rose by 1.45% and the Hang Seng Tech Index increased by 2.66% during the midday close [1] - Semiconductor products and equipment, as well as metals and mining sectors, showed significant gains, while passenger airlines and construction products sectors experienced notable declines [1] Individual Stocks Performance - Zijin Mining International surged by 12.02%, followed by SMIC with a 9.3% increase, and Kuaishou-W rising by 6.56% [1] - Other notable gainers include Huahong Semiconductor up by 5.44%, Hengrui Medicine up by 5.29%, and Xinda Biopharmaceuticals up by 4.77% [1] - Conversely, Beike-W fell by 6.21% and Yihua Tong dropped by 6.42% [1] - MIRXES-B saw a significant increase of 13.52%, while Tianqi Lithium rose by 13.04% [1]